Home > Insider Trading > Filing (0001225208-24-000107)

Filing Details

Accession Number:: 0001225208-24-000107
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-02 20:30:20
Reporting Period:: 2023-12-29

Accepted Time:: 2024-01-02 20:30:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885725	Boston Scientific Corp	BSX	Surgical & Medical Instruments & Apparatus (3841)	042695240

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1484186	Michael Joseph Fitzgerald	300 Boston Scientific Way Marlborough MA 01752-1234	Evp & Group Pres, Cardiology	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-29	58,189	$16.31	256,181	No	4	M	Direct
Common Stock	Disposition	2023-12-29	81,940	$57.50	174,241	No	4	S	Direct
Common Stock	Acquisiton	2024-01-01	21,799	$0.00	196,040	No	4	M	Direct
Common Stock	Disposition	2024-01-01	10,908	$57.81	185,132	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-12-29	58,189	$0.00	58,189	$16.31
Common Stock	Performance Share Units	Disposition	2024-01-01	21,799	$0.00	21,799	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-02-23	No	4	M	Direct
0	2023-12-31	2023-12-31	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	68,004	Indirect	By 401(k)
Common Stock	4,344	Indirect	By Child

Footnotes

The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c).
On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023.
Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.